Business
Itonis Pharmaceuticals Authorizes Start of Emesyl(R) Inaugural Production Run
Itonis Pharmaceuticals Authorizes Start of Emesyl(R) Inaugural Production Run.
About this update from Itonis, Inc.
[{"type":"text","content":"\n \n \n Itonis Pharmaceuticals Authorizes Start of Emesyl(R) Inaugural Production Run\n \n \nItonis Pharmaceuticals Authorizes Start of Emesyl(R) Inaugural Production Run\n \n LAGUNA HILLS, CA--(Marketwired - Jun 25, 2014) - Itonis, Inc. (PINKSHEETS: ITNS) Itonis is pleased to announce that, with the finalization of its new packaging design and product labeling, it has given the go ahead to Oasis Health Products to produce 16,000 units of its Emesyl® homeopathic product. Itonis has pre-paid necessary funds to Oasis to commence the inaugural production run. \n \"The Company is excited that we have finally developed Emesyl® to start production. We are in good hands with Oasis Health Products and we cannot wait for the first Emesyl® that we can proudly market and place on store shelves,\" says Mark Cheung, the Company's CEO.\n About Itonis Pharmaceuticals\n Itonis Pharmaceuticals, a division of Itonis, Inc., is headed by Charles Hensley, Ph.D., and its mission is to create and market over-the-counter and prescription homeopathic products that better people's lives. Dr. Hensley is a pioneer in the development and marketing of safe and effective therapeutic nutraceutical and homeopathic preparations. He was a founder of the company that launched the Zicam® Cold Remedy, making the product a household name and forever changing the marketing and product placement paradigm for homeopathic drugs in the United States. Dr. Hensley and his team plan to use the same methodologies to revolutionize the treatment of several other common ailments and other chronic diseases. \n About Itonis, Inc. \n Itonis, Inc. was incorporated in the state of Nevada on July 5, 2005 under the name of Kenshou, Inc., which later changed to Itonis, Inc. on December 2, 2005. Please visit www.itonisholdings.com. \n Safe Harbor:\n Statements in this press release may constitute forward-looking statements and are subject to numerous risks and uncertainties, including the failure to complete successfully the development of new or enhanced products, the Company's future capital needs, the lack of market demand for any new or enhanced products the Company may develop, any actions by the Company's affiliates that may be adverse to the Company, the success of competitive products, other economic factors affecting the Company and its markets, seasonal cha...